Zusammenfassung
In früheren Studien an Ratten wurde gezeigt, dass eine Dysfunktion der Hypothalamus-Hypophysen-Nebennieren(HHN)-Achse vor allen Dingen im Bereich des Hypothalamus lokalisiert ist (genetisch determinierte inadäquate Sekretion von corticotropin-releasing-hormone). Dieser Defekt trug entscheidend zur Entwicklung einer Modell-Arthritis in diesen Tiermodellen bei. Beim Menschen stellte sich diese Situation allerdings anders dar: hier scheint der Defekt vor allen Dingen im Bereich der Nebenniere lokalisiert zu sein, wodurch es zu einer inadäquat niedrigen Kortisolproduktion bei chronisch entzündlichen Erkrankungen in Relation zum systemischen Entzündungsausmaß kommt. Neben Kortisol ist auch ein anderes adrenales Steroid, das Dehydroepiandrosteron (DHEA), drastisch erniedrigt. Die Ursache für die Störung der adrenalen Steroidproduktion bei rheumatoider Arthritis und anderen chronisch entzündlichen Erkrankungen ist zur Zeit nicht bekannt. Da DHEA sowohl den Tumor-Nekrose-Faktor Alpha (TNFα) als auch Interleukin(IL)-6 in vitro und in vivo hemmen kann, hat dieses adrenale Steroidhormon ebenso wie Kortisol wahrscheinlich eine antiinflammatorische Bedeutung. Die Wirkung des DHEA ist dabei durch eine Hemmung des nukleären Faktors NFκB vermittelt. Desweiteren kann DHEA in peripheren Zellen wie beispielsweise Makrophagen zu antiinflammatorisch wirksamen Geschlechtshormonen wie Testosteron umgewandelt werden. Bei Patienten mit chronisch entzündlichen Erkrankungen ist gerade DHEA deutlich erniedrigt, was durch eine zusätzliche Glukokortikoidtherapie noch verstärkt wird. Dieser Überblick demonstriert, warum gerade die Produktion von DHEA bei chronisch entzündlichen Erkrankungen erniedrigt ist. Die Bedeutung der DHEA-Verarmung wird am Beispiel der Osteoporose demonstriert. Es wird dargestellt, weshalb die parallele Therapie mit Glukokortikoiden plus DHEA eine interessante Therapieoption bei chronisch entzündlichen Erkrankungen darstellt.
Summary
A dysfunction of the hypothalamic - pituitary - adrenal (HPA) axis was found in animal models of chronic inflammatory diseases, and the defect was located in more central portions of the HPA axis. This defect of neuroendocrine regulatory mechanisms contributes to the onset of the model disease. Since these first observations in animal models were made, evidence has accumulated that the possible defect in the HPA axis in humans is more distal to the hypothalamus or pituitary gland: In chronic inflammatory diseases, such as rheumatoid arthritis, an alteration of the HPA stress response results in inappropriately low cortisol secretion in relation to adrenocorticotropic hormone (ACTH) secretion. Furthermore, it has recently been shown that the serum levels of another adrenal hormone, dehydroepiandrosterone (DHEA), were significantly lower after ACTH stimulation in patients with rheumatoid arthritis without prior corticosteroids than in healthy controls. These studies clearly indicate that chronic inflammation alters, particularly, the adrenal response. However, at this point, the reason for the specific alteration of adrenal function in relation to pituitary function remains to be determined.
Since one of the down-regulated adrenal hormones, DHEA, is an inhibitor of cytokines due to an inhibition of nuclear factor-kappa B (NF-κB) activation, low levels of this hormone may be deleterious in chronic inflammatory diseases. We have recently demonstrated that DHEA is a potent inhibitor of IL-6, which confirmed an earlier study in mice. Since IL-6 is an important factor for B lymphocyte differentiation, the missing down-regulation of this cytokine, and others such as TNF, may be a significant risk factor in rheumatic diseases. Since in these patients, administration of prednisolone or the chronic inflammatory process itself alters adrenal function, endogenous adrenal hormones in relation to proinflammatory cytokines change. Furthermore, these mechanisms may also lead to shifts in steroidogenesis which have been demonstrated in chronic inflammatory diseases. It was repeatedly demonstrated that the serum level of the sulphated form of DHEA (DHEAS) was significantly lower in patients with chronic inflammatory diseases. Since DHEAS is the pool for peripheral sex steroids, such as testosterone and 17β-estradiol, lack of this hormone leads to a significant sex hormone deficiency in the periphery.
This overview will demonstrate mechanisms why DHEAS is reduced in chronic inflammatory diseases. The importance of DHEAS deficiency will be demonstrated with respect to osteoporosis. As a consequence, we suggest a combined therapy with corticosteroids plus DHEA in chronic inflammatory diseases.
References
Angele MK, Ayala A, Monfils BA, Cioffi WG, Bland KI, Chaudry IH (1998) Testosterone and/or low estradiol: normally required but harmful immunologically for males after trauma-hemorrhage. J Trauma 44: 78–85
Araghi-Niknam M, Liang B, Zhang Z, Ardestani SK, Watson RR (1997) Modulation of immune dysfunction during murine leukaemia retrovirus infection of old mice by dehydroepiandrosterone sulphate (DHEAS). Immunology 90: 344–349
Araghi-Niknam M, Zhang Z, Jiang S, Call O, Eskelson CD, Watson RR (1997) Cytokine dysregulation and increased oxidation is prevented by dehydroepiandrosterone in mice infected with murine leukemia retrovirus. Proc Soc Exp Biol Med 216: 386–391
Araneo B, Daynes R (1995) Dehydroepiandrosterone functions as more than an antiglucocorticoid in preserving immunocompetence after thermal injury. Endocrinology 136: 393–401
Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A (2000) Tumor necrosis factoralpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 275: 4858–4864
Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R, Manolagas SC (1995) Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 95: 2886–2895
Bernardini R, Kamilaris TC, Calogero AE, Johnson EO, Gomez MT, Gold PW, Chrousos GP (1990) Interactions between tumor necrosis factor-alpha, hypothalamic corticotropin-releasing hormone, and adrenocorticotropin secretion in the rat. Endocrinology 126: 2876–2881
Besedovsky H, Sorkin E, Felix D, Haas H (1977) Hypothalamic changes during the immune response. Eur J Immunol 7: 323–325
Besedovsky HO, Del Rey A (1996) Immune-neuro-endocrine interactions. Endocr Rev 17: 64–102
Besedovsky HO, Del Rey A, Sorkin E, Dinarello C (1986) Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 233: 652–654
Bijlsma JW (1999) Can we use steroid hormones to immunomodulate rheumatic diseases? Rheumatoid arthritis as an example. Ann N Y Acad Sci 876: 366–76; discussion 376-7: 366–376
Blauer KL, Poth M, Rogers WM, Bernton EW (1991) Dehydroepiandrosterone antagonizes the suppressive effects of dexamethasone on lymphocyte proliferation. Endocrinology 129: 3174–3179
Boccuzzi G, Aragno M, Seccia M, Brignardello E, Tamagno E, Albano E, Danni O, Bellomo G (1997) Protective effect of dehydroepiandrosterone against copper-induced lipid peroxidation in the rat. Free Radic Biol Med 22: 1289–1294
Browne ES, Porter JR, Correa G, Abadie J, Svec F (1993) Dehydroepiandrosterone regulation of the hepatic glucocorticoid receptor in the Zucker rat. The obesity research program. J Steroid Biochem Mol Biol 45: 517–524
Canning MB, Billington WD (1983) Hormonal regulation of immunoglobulins and plasma cells in the mouse uterus. J Endocrinol 97: 419–424
Carr DJ (1998) Increased levels of IFN-gamma in the trigeminal ganglion correlate with protection against HSV-1-induced encephalitis following subcutaneous administration with androstenediol. J Neuroimmunol 89: 160–167
Chesney RW, Mazess RB, Hamstra AJ, Deluca HF, O'Reagan S (1978) Reduction of serum-1, 25-dihydroxyvitamin-D3 in children receiving glucocorticoids. Lancet 2: 1123–1125
Correale J, Arias M, Gilmore W (1998) Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol 161: 3365–3374
Cutolo M, Balleari E, Giusti M, Monachesi M, Accardo S (1986) Sex hormone status in women suffering from rheumatoid arthritis. J Rheumatol 13: 1019–1023
Cutolo M, Balleari E, Giusti M, Monachesi M, Accardo S (1988) Sex hormone status of male patients with rheumatoid arthritis: evidence of low serum concentrations of testosterone at baseline and after human chorionic gonadotropin stimulation. Arthritis Rheum 31: 1314–1317
Cutolo M, Foppiani L, Prete C, Ballarino P, Sulli A, Villaggio B, Seriolo B, Giusti M, Accardo S (1999) Hypothalamic-pituitary- adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids. J Rheumatol 26: 282–288
Danenberg HD, Alpert G, Lustig S, Ben-Nathan D (1992) Dehydroepiandrosterone protects mice from endotoxin toxicity and reduces tumor necrosis factor production. Antimicrob Agents Chemother 36: 2275–2279
Dashtaki R, Whorton AR, Murphy TM, Chitano P, Reed W, Kennedy TP (1998) Dehydroepiandrosterone and analogs inhibit DNA binding of AP-1 and airway smooth muscle proliferation. J Pharmacol Exp Ther 285: 876–883
Daynes RA, Araneo BA, Ershler WB, Maloney C, Li GZ, Ryu SY (1993) Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol 150: 5219–5230
de la Torre B, Fransson J, Scheynius A (1995) Blood dehydroepiandrosterone sulphate (DHEAS) levels in pemphigoid/ pemphigus and psoriasis. Clin Exp Rheumatol 13: 345–348
Dent PB, Walker N (1998) Intra-articular corticosteroids in the treatment of juvenile rheumatoid arthritis. Curr Opin Rheumatol 10: 475–480
Deshpande R, Khalili H, Pergolizzi RG, Michael SD, Chang MD (1997) Estradiol down-regulates LPS-induced cytokine production and NFκB activation in murine macrophages. Am J Reprod Immunol 38: 46–54
Di Santo E, Foddi MC, Ricciardi-Castagnoli P, Mennini T, Ghezzi P (1996) DHEAS inhibits TNF production in monocytes, astrocytes and microglial cells. Neuroimmunomodulation 3: 285–288
Dougados M, Nahoul K, Benhamou L, Jungers P, Laplane D, Amor B (1984) Study of plasma androgens in women with autoimmune diseases. Rev Rhum Mal Osteoartic 51: 145–149
Feher KG, Feher T (1984) Plasma dehydroepiandrosterone, dehydroepiandrosterone sulphate and androsterone sulphate levels and their interaction with plasma proteins in rheumatoid arthritis. Exp Clin Endocrinol 84: 197–202
Fleshner M, Goehler LE, Hermann J, Relton JK, Maier SF, Watkins LR (1995) Interleukin-1 beta induced corticosterone elevation and hypothalamic NE depletion is vagally mediated. Brain Res Bull 37: 605–610
Folomeev M, Dougados M, Beaune J, Kouyoumdjian JC, Nahoul K, Amor B, Alekberova Z (1992) Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus 1: 191–195
Formiga F, Moga I, Nolla JM, Navarro MA, Bonnin R, Roig-Escofet D (1997) The association of dehydroepiandrosterone sulphate levels with bone mineral density in systemic lupus erythematosus. Clin Exp Rheumatol 15: 387–392
Giltay EJ, van Schaardenburg D, Gooren LJ, Dijkmans BA (1999) Dehydroepiandrosterone sulfate in patients with rheumatoid arthritis. Ann N Y Acad Sci 876: 152–4: 152–154
Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, Manolagas SC (1992) 17 beta-estradiol inhibits interleukin- 6 production by bone marrowderived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 89: 883–891
Gordon D, Beastall GH, Thomson JA, Sturrock RD (1986) Androgenic status and sexual function in males with rheumatoid arthritis and ankylosing spondylitis. Q J Med 60: 671–679
Hales DB (1992) Interleukin-1 inhibits Leydig cell steroidogenesis primarily by decreasing 17 alpha-hydroxylase/C17-20 lyase cytochrome P450 expression. Endocrinology 131: 2165–2172
Hedman M, Nilsson E, de la TB (1992) Low blood and synovial fluid levels of sulpho-conjugated steroids in rheumatoid arthritis. Clin Exp Rheumatol 10: 25–30
Henderson NK, Sambrook PN (1996) Relationship between osteoporosis and arthritis and effect of corticosteroids and other drugs on bone. Curr Opin Rheumatol 8: 365–369
Hernandez-Pando R, De La Luz S, Orozco H, Arriaga K, Pavon L, Al-Nakhli SA, Rook GA (1998) The effects of androstenediol and dehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice. Immunology 95: 234–241
Herrmann M, Zietz B, Schölmerich J, Straub RH (2000) Modulation of steroidogenesis by cytokines and growth factors - are there consequences for chronic inflammatory diseases? (submitted)
Hodgson SF (1990) Corticosteroid-induced osteoporosis. Endocrinol Metab Clin North Am 19: 95–111
Hu Y, Cardounel A, Gursoy E, Anderson P, Kalimi M (2000) Anti-stress effects of dehydroepiandrosterone: protection of rats against repeated immobilization stress-induced weight loss, glucocorticoid receptor production, and lipid peroxidation. Biochem Pharmacol 59: 753–762
Inserra P, Zhang Z, Ardestani SK, Araghi-Niknam M, Liang B, Jiang S, Shaw D, Molitor M, Elliott K, Watson RR (1998) Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice. Proc Soc Exp Biol Med 218: 76–82
Irvine WJ, Toft AD, Wilson KS, Fraser R, Wilson A, Young J, Hunter WM, Ismail AA, Burger PE (1974) The effect of synthetic corticotropin analogues on adrenocortical, anterior pituitary and testicular function. J Clin Endocrinol Metab 39: 522–529
Jaattela M, Ilvesmaki V, Voutilainen R, Stenman UH, Saksela E (1991) Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology 128: 623–629
Jablons DM, Mule JJ, McIntosh JK, Sehgal PB, May LT, Huang CM, Rosenberg SA, Lotze MT (1989) IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J Immunol 142: 1542–1547
Kalimi M, Shafagoj Y, Loria R, Padgett D, Regelson W (1994) Anti-glucocorticoid effects of dehydroepiandrosterone (DHEA). Mol Cell Biochem 131: 99–104
Kanda N, Tsuchida T, Tamaki K (1996) Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells. Clin Exp Immunol 106: 410–415
Kanda N, Tsuchida T, Tamaki K (1997) Testosterone suppresses anti-DNA antibody production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 40: 1703–1711
Karlson P (1995) Adolf Butenandt (1903–1995). Nature 373: 660
Kasperk CH, Wakley GK, Hierl T, Ziegler R (1997) Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. J Bone Miner Res 12: 464–471
Khalil A, Lehoux JG, Wagner RJ, Lesur O, Cruz S, Dupont E, Jay-Gerin JP, Wallach J, Fulop T (1998) Dehydroepiandrosterone protects low density lipoproteins against peroxidation by free radicals produced by gamma-radiolysis of ethanol-water mixtures. Atherosclerosis 136: 99–107
Kim HR, Ryu SY, Kim HS, Choi BM, Lee EJ, Kim HM, Chung HT (1995) Administration of dehydroepiandrosterone reverses the immune suppression induced by high dose antigen in mice. Immunol Invest 24: 583–593
Kimonides VG, Spillantini MG, Sofroniew MV, Fawcett JW, Herbert J (1999) Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures. Neuroscience 89: 429–436
Kimura M, Tanaka S, Yamada Y, Kiuchi Y, Yamakawa T, Sekihara H (1998) Dehydroepiandrosterone decreases serum tumor necrosis factor-alpha and restores insulin sensitivity: independent effect from secondary weight reduction in genetically obese Zucker fatty rats. Endocrinology 139: 3249–3253
Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333: 142–146
Kominami S, Ogawa N, Morimune R, De Ying H, Takemori S (1992) The role of cytochrome b5 in adrenal microsomal steroidogenesis. J Steroid Biochem Mol Biol 42: 57–64
Kumpfel T, Then BF, Friess E, Uhr M, Yassouridis A, Trenkwalder C, Holsboer F (1999) Dehydroepiandrosterone response to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing hormone test in patients with multiple sclerosis. Neuroendocrinology 70: 431–438
Kuwano Y, Fujikawa H, Watanabe A, Shimodaira K, Sekizawa A, Saito H, Yanaihara T (1997) 3Beta-hydroxysteroid dehydrogenase activity in human osteoblast-like cells. Endocr J 44: 847–853
Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A, Candas B (1997) Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 82: 3498–3505
Lahita RG, Bradlow HL, Ginzler E, Pang S, New M (1987) Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 30: 241–248
Loria RM, Inge TH, Cook SS, Szakal AK, Regelson W (1988) Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). J Med Virol 26: 301–314
Lucas JA, Ahmed SA, Casey ML, MacDonald PC (1985) Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroisoandrosterone. J Clin Invest 75: 2091–2093
Luo S, Labrie C, Belanger A, Labrie F (1997) Effect of dehydroepiandrosterone on bone mass, serum lipids, and dimethylbenz(a)anthracene-induced mammary carcinoma in the rat. Endocrinology 138: 3387–3394
Mackworth-Young CG, Parke AL, Morley KD, Fotherby K, Hughes GR (1983) Sex hormones in male patients with systemic lupus erythematosus: a comparison with other disease groups. Eur J Rheumatol Inflamm 6: 228–232
Masi AT, Bijlsma JW, Chikanza IC, Pitzalis C, Cutolo M (1999) Neuroendocrine, immunologic, and microvascular systems interactions in rheumatoid arthritis: physiopathogenetic and therapeutic perspectives. Semin Arthritis Rheum 29: 65–81
Masi AT, Chrousos GP, Bornstein SR (1999) Enigmas of adrenal androgen and glucocorticoid dissociation in premenopausal onset rheumatoid arthritis. J Rheumatol 26: 247–250
Masi AT, Josipovic DB, Jefferson WE (1984) Low adrenal androgenic-anabolic steroids in women with rheumatoid arthritis (RA): gas-liquid chromatographic studies of RA patients and matched normal control women indicating decreased 11-deoxy-17-ketosteroid excretion. Semin Arthritis Rheum 14: 1–23
Mastorakos G, Chrousos GP, Weber JS (1993) Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 77: 1690–1694
Mateo L, Nolla JM, Bonnin MR, Navarro MA, Roig-Escofet D (1995) Sex hormone status and bone mineral density in men with rheumatoid arthritis. J Rheumatol 22: 1455–1460
Mauduit C, Gasnier F, Rey C, Chauvin MA, Stocco DM, Louisot P, Benahmed M (1998) Tumor necrosis factor-alpha inhibits leydig cell steroidogenesis through a decrease in steroidogenic acute regulatory protein expression. Endocrinology 139: 2863–2868
May M, Holmes E, Rogers W, Poth M (1990) Protection from glucocorticoid induced thymic involution by dehydroepiandrosterone. Life Sci 46: 1627–1631
Miller WL, Auchus RJ, Geller DH (1997) The regulation of 17,20 lyase activity. Steroids 62: 133–142
Mirone L, Altomonte L, D'Agostino P, Zoli A, Barini A, Magaro M (1996) A study of serum androgen and cortisol levels in female patients with rheumatoid arthritis. Correlation with disease activity. Clin Rheumatol 15: 15–19
Mohan PF, Jacobson MS (1993) Inhibition of macrophage superoxide generation by dehydroepiandrosterone. Am J Med Sci 306: 10–15
Morand EF (1998) Corticosteroids in the treatment of rheumatologic diseases. Curr Opin Rheumatol 10: 179–183
Muzulu SI, Howlett TA (1998) Polymyalgia rheumatica presenting after successful treatment of Cushing's disease. Br J Rheumatol 37: 804–805
Neeck G, Federlin K, Graef V, Rusch D, Schmidt KL (1990) Adrenal secretion of cortisol in patients with rheumatoid arthritis. J Rheumatol 17: 24–29
Nilsson E, de la TB, Hedman M, Goobar J, Thorner A (1994) Blood dehydroepiandrosterone sulphate (DHEAS) levels in polymyalgia rheumatica/giant cell arteritis and primary fibromyalgia. Clin Exp Rheumatol 12: 415–417
Nordin BE, Robertson A, Seamark RF, Bridges A, Philcox JC, Need AG, Horowitz M, Morris HA, Deam S (1985) The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women. J Clin Endocrinol Metab 60: 651–657
Norton SD, Harrison LL, tYowell R, Araneo BA (1997) Administration of dehydroepiandrosterone sulfate retards onset but not progression of autoimmune disease in NZB/W mice. Autoimmunity 26: 161–171
Olbricht T, Benker G (1993) Glucocorticoid- induced osteoporosis: pathogenesis, prevention and treatment, with special regard to the rheumatic diseases. J Intern Med 234: 237–244
Onel KB (2000) Advances in the medical treatment of juvenile rheumatoid arthritis. Curr Opin Pediatr 12: 72–75
Orava M, Voutilainen R, Vihko R (1989) Interferon-gamma inhibits steroidogenesis and accumulation of mRNA of the steroidogenic enzymes P450scc and P450c17 in cultured porcine Leydig cells. Mol Endocrinol 3: 887–894
Paavonen T, Andersson LC, Adlercreutz H (1981) Sex hormone regulation of in vitro immune response. Estradiol enhances human B cell maturation via inhibition of suppressor T cells in pokeweed mitogen-stimulated cultures. J Exp Med 154: 1935–1945
Padgett DA, Loria RM (1998) Endocrine regulation of murine macrophage function: effects of dehydroepiandrosterone, androstenediol, and androstenetriol. J Neuroimmunol 84: 61–68
Padgett DA, Loria RM, Sheridan JF (1997) Endocrine regulation of the immune response to influenza virus infection with a metabolite of DHEAandrostenediol. J Neuroimmunol 78: 203–211
Parker LN, Levin ER, Lifrak ET (1985) Evidence for adrenocortical adaptation to severe illness. J Clin Endocrinol Metab 60: 947–952
Passeri G, Girasole G, Jilka RL, Manolagas SC (1993) Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology 133: 822–828
Passeri G, Girasole G, Manolagas SC, Jilka RL (1994) Endogenous production of tumor necrosis factor by primary cultures of murine calvarial cells: influence on IL-6 production and osteoclast development. Bone Miner 24: 109–126
Path G, Bornstein SR, Spath-Schwalbe E, Scherbaum WA (1996) Direct effects of interleukin-6 on human adrenal cells. Endocr Res 22: 867–873
Polley HF, Slocumb CH (1976) Behind the scenes with cortisone and ACTH. Mayo Clin Proc 51: 471–477
Poynter ME, Daynes RA (1998) Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273: 32833–32841
Pung OJ, Tucker AN, Vore SJ, Luster MI (1985) Influence of estrogen on host resistance: increased susceptibility of mice to Listeria monocytogenes correlates with depressed production of interleukin 2. Infect Immun 50: 91–96
Ralston SH, Russell RG, Gowen M (1990) Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J Bone Miner Res 5: 983–988
Ray A, Prefontaine KE, Ray P (1994) Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem 269: 12940–12946
Robinzon B, Cutolo M (1999) Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids? Rheumatology (Oxford) 38: 488–495
Rom WN, Harkin T (1991) Dehydroepiandrosterone inhibits the spontaneous release of superoxide radical by alveolar macrophages in vitro in asbestosis. Environ Res 55: 145–156
Sambrook PN, Eisman JA, Champion GD, Pocock NA (1988) Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 31: 973–978
Sambrook PN, Eisman JA, Champion GD, Pocock NA (1988) Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 31: 973–978
Scheven BA, Milne JS (1998) Dehydroepiandrosterone (DHEA) and DHEAS interact with 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) to stimulate human osteoblastic cell differentiation. Life Sci 62: 59–68
Schmidt M, Kreutz M, Löffler G, Schölmerich J, Straub RH (2000) Conversion of dehydroepiandrosterone to downstream steroid hormones in macrophages. J Endocrinol 164: 161–169
Senecal JL, Uthman I, Beauregard H (1994) Cushing's disease-induced remission of severe rheumatoid arthritis. Arthritis Rheum 37: 1826
Shafagoj Y, Opoku J, Qureshi D, Regelson W, Kalimi M (1992) Dehydroepiandrosterone prevents dexamethasone- induced hypertension in rats. Am J Physiol 263: E210–E213
Späth-Schwalbe E, Born J, Schrezenmeier H, Bornstein SR, Stromeyer P, Drechsler S, Fehm HL, Porzsolt F (1994) Interleukin-6 stimulates the hypothalamus- pituitary-adrenocortical axis in man. J Clin Endocrinol Metab 79: 1212–1214
Spector TD, Perry LA, Tubb G, Silman AJ, Huskisson EC (1988) Low free testosterone levels in rheumatoid arthritis. Ann Rheum Dis 47: 65–68
Spencer NF, Norton SD, Harrison LL, Li GZ, Daynes RA (1996) Dysregulation of IL-10 production with aging: possible linkage to the age-associated decline in DHEA and its sulfated derivative. Exp Gerontol 31: 393–408
Straub RH, Glück T, Cutolo M, Georgi J, Helmke K, Schölmerich J, Vaith P, Lang B (2000) The adrenal steroid status in relation to inflammatory cytokines (IL-6 and TNF) in polymyalgia rheumatica. Rheumatology 39: 624–631
Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Schölmerich J, Falk W, Lang B (1998) Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin- 6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 83: 2012–2017
Straub RH, Miller LE, Schölmerich J, Zietz B (2000) Cytokines and hormones as possible links between endocrinosenescence and immunosenescence. J Neuroimmunol (in press)
Straub RH, Muller-Ladner U, Lichtinger T, Schölmerich J, Menninger H, Lang B (1997) Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying antirheumatic drugs. Br J Rheumatol 36: 1298–1303
Straub RH, Vogl D, Gross V, Lang B, Schölmerich J, Andus T (1998) Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Am J Gastroenterol 93: 2197–2202
Straub RH, Zeuner M, Antoniou E, Schölmerich J, Lang B (1996) Dehydroepiandrosterone sulfate is positively correlated with soluble interleukin 2 receptor and soluble intercellular adhesion molecule in systemic lupus erythematosus. J Rheumatol 23: 856–861
Straub RH, Zeuner M, Lock G, Schölmerich J, Lang B (1997) High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis. Br J Rheumatol 36: 426–432
Suzuki Y, Ichikawa Y, Saito E, Homma M (1983) Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 32: 151–156
Szathmari M, Szucs J, Feher T, Hollo I (1994) Dehydroepiandrosterone sulphate and bone mineral density. Osteoporos Int 4: 84–88
Tabata N, Tagami H, Terui T (1997) Dehydroepiandrosterone may be one of the regulators of cytokine production in atopic dermatitis. Arch Dermatol Res 289: 410–414
Tamagno E, Aragno M, Boccuzzi G, Gallo M, Parola S, Fubini B, Poli G, Danni O (1998) Oxygen free radical scavenger properties of dehydroepiandrosterone. Cell Biochem Funct 16: 57–63
Tani-Ishii N, Tsunoda A, Teranaka T, Umemoto T (1999) Autocrine regulation of osteoclast formation and bone resorption by IL-1 alpha and TNF alpha. J Dent Res 78: 1617–1623
Turner RT, Lifrak ET, Beckner M, Wakley GK, Hannon KS, Parker LN (1990) Dehydroepiandrosterone reduces cancellous bone osteopenia in ovariectomized rats. Am J Physiol 258: E673–E677
Tyrell JB, Aron DC, Forsham PH (1995) Glucocorticoids and adrenal androgens. In: Greenspan FS (ed) Basic and Clinical Endocrinology. Appleton & Lange, East Norwalk, pp 323–362
Udagawa N, Takahashi N, Katagiri T, Tamura T, Wada S, Findlay DM, Martin TJ, Hirota H, Taga T, Kishimoto T (1995) Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med 182: 1461–1468
Uthman I, Senecal JL (1995) Onset of rheumatoid arthritis after surgical treatment of Cushing's disease. J Rheumatol 22: 1964–1966
Vaitukaitis JL, Dale SL, Melby JC (1969) Role of ACTH in the secretion of free dehydroepiandrosterone and its sulfate ester in man. J Clin Endocrinol Metab 29: 1443–1447
van Vollenhoven RF (1998) Corticosteroids in rheumatic disease. Understanding their effects is key to their use. Postgrad Med 103: 137–142
van Vollenhoven RF, Engleman EG, McGuire JL (1994) An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 37: 1305–1310
van Vollenhoven RF, Engleman EG, McGuire JL (1995) Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 38: 1826–1831
van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL (1998) Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 25: 285–289
van Vollenhoven RF, Park JL, Genovese MC, West JP, McGuire JL (1999) A double- blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 8: 181–187
Verhoeven AC, Boers M (1997) Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol 24: 1495–1503
Wichmann MW, Ayala A, Chaudry IH (1997) Male sex steroids are responsible for depressing macrophage immune function after trauma-hemorrhage. Am J Physiol 273: C1335–C1340
Wilder RL (1996) Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis. J Rheumatol Suppl 44: 10–2: 10–12
Williams PJ, Jones RH, Rademacher TW (1997) Reduction in the incidence and severity of collagen-induced arthritis in DBA/1 mice, using exogenous dehydroepiandrosterone. Arthritis Rheum 40: 907–911
Wright BE, Porter JR, Browne ES, Svec F (1992) Antiglucocorticoid action of dehydroepiandrosterone in young obese Zucker rats. Int J Obes Relat Metab Disord 16: 579–583
Xia-Zhang L, Xiao E, Ferin M (1995) A 5-day estradiol therapy, in amounts reproducing concentrations of the earlymid follicular phase, prevents the activation of the hypothalamo-pituitary-adrenal axis by interleukin-1 alpha in the ovariectomized rhesus monkey. J Neuroendocrinol 7: 387–392
Xiong Y, Hales DB (1997) Differential effects of tumor necrosis factor-alpha and interleukin-1 on 3 beta-hydroxysteroid dehydrogenase/delta 5—>delta 4 isomerase expression in mouse Leydig cells. Endocrine 7: 295–301
Yakushiji F, Kita M, Hiroi N, Ueshiba H, Monma I, Miyachi Y (1995) Exacerbation of rheumatoid arthritis after removal of adrenal adenoma in Cushing's syndrome. Endocr J 42: 219–223
Young DG, Skibinski G, Mason JI, James K (1999) The influence of age and gender on serum dehydroepiandrosterone sulphate (DHEA-S), IL-6, IL-6 soluble receptor (IL-6 sR) and transforming growth factor beta 1 (TGF-beta1) levels in normal healthy blood donors. Clin Exp Immunol 117: 476–481
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Straub, R.H., Schölmerich, J. & Zietz, B. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases - substitutes of adrenal and sex hormones. Z Rheumatol 59 (Suppl 2), II108–II118 (2000). https://doi.org/10.1007/s003930070004
Published:
Issue Date:
DOI: https://doi.org/10.1007/s003930070004